Radient Pharmaceuticals Corporation fka RXPC

[Gold Seeker]

The revocation is not just temporary. Radient could at some point in the future file for stock registration but along with the registration filing, it would be required to submit audited SEC financial reports for the preceeding 3 years.

With all the former management gone, it would be exceptionally difficult to provide those SEC reports. Accordingly, the value of the RXPC shell has diminished even more with the recent change in management.

"Non-Trading Non-ReportingNormally only a shareholder base
No symbol
May or may not have been a reporting company
Must file with SEC full business information and audits to become reporting
Market Maker must file a new 15c211 with the NASD to get symbol This type of shell is least attractive"

http://gopublic.com/public-shells-types.html

No one is going to want Radient as a shell. Not only do you have a bunch of sharehoders to deal with, you have $25 to $30 million in debt to deal with along with the preceeding 3 years of audited financial reports to deal with.

Radient will just never trade again. It is just too expensive and too difficult and there is just no value left in the company, no patents, nothing but the lab equipment and that may have already left for Hong Kong.